To appraise the clinical and cost effectiveness of cabozantinib within its marketing authorisation for previously treated advanced hepatocellular carcinoma.
|
Status
|
In progress
|
|
Decision
|
Selected
|
| Process |
STA 2018
|
| ID number |
3917
|
Provisional Schedule
| Committee meeting: 1 |
02 August 2022 |
| Expected publication |
12 October 2022 |
Project Team
| Project lead |
Louise Jafferally |
Email enquiries
| External Assessment Group |
School of Health and Related Research (ScHARR), University of Sheffield |
Stakeholders
| Companies sponsors |
Ipsen (cabozantinib) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| |
Welsh Government |
| Patient carer groups |
British Liver Trust |
| Professional groups |
Association of Cancer Physicians |
| |
British Association for the Study of the Liver (BASL) |
| |
Cancer Research UK |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| Assessment group |
None |
| Comparator companies |
Bayer (regorafenib) (confidentiality agreement signed, participating) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Institute of Cancer Research |
|
Date
|
Update
|
|
22 November 2021
|
Invitation to participate |
|
23 July 2021
|
We recently contacted all stakeholders for the appraisal of cabozantinib for previously treated advanced hepatocellular carcinoma [ID3917] regarding a delay to this topic for operational reasons.
Cabozantinib for previously treated advanced hepatocellular carcinoma has now been rescheduled into the work programme and the appraisal is due to start late November 2021 and will be discussed at committee in early August 2022.
The new timelines are subject to the work programme capacity and we will continue to review our plans and update our stakeholders accordingly. |
|
07 May 2021
|
NICE has taken the decision to pause this appraisal due to operational reasons. The timelines are currently to be confirmed. |
|
19 March 2021 - 13 April 2021
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
|
05 February 2021
|
In progress. Topic in progress |
For further information on our processes and methods, please see our CHTE processes and methods manual